GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc. (GLSI) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D+ (1.8) | D- (0.8) | C+ (2.6) | C+ (2.6) | C- (2.1) |
| 2026-11-05 | C+ (2.5) | D+ (1.8) | D- (0.8) | B- (3.0) | C+ (2.7) | C (2.2) |
| 2026-10-29 | C+ (2.5) | D+ (1.8) | D- (0.8) | B (3.4) | C+ (2.7) | C (2.2) |
| 2026-10-22 | C+ (2.5) | C- (1.9) | D- (0.8) | B (3.3) | C+ (2.6) | C (2.2) |
| 2026-10-15 | C+ (2.5) | D+ (1.8) | D- (0.8) | C- (2.0) | C+ (2.6) | C- (2.0) |